GENE ONLINE|News &
Opinion
Blog

RNAi Therapeutics
M&A RNA Therapeutics
Following Two Years of Promising RNAi Collab, Novo Nordisk Decides to Acquire Dicerna for $3.3 Billion
2021-11-18
R&D RNAi Therapeutics
Alnylam Aims to Obtain “Top 5 Biotech” Tag By 2025
2021-01-12
Funding RNAi Therapeutics
Maryland Biopharma Raises $105 Million in Series D to Fund Development of RNAi Therapeutics
2020-10-24
Trials & Approvals RNAi Therapeutics
Alnylam’s RNAi-Based Therapy Lumasiran Impresses in Phase 3 Primary Hyperoxaluria Trials
2020-06-12
LATEST
ImmunityBio’s ANKTIVA® Granted FDA Approval: Breakthrough IL-15 Receptor Agonist First-in-Class for BCG-Unresponsive Non-Muscle Invasive Bladder Cancer
2024-04-24
Takeda, Astellas, and Sumitomo Mitsui Banking Declare Agreement For Early Drug Discovery Program Incubation in Joint Venture
2024-04-23
Ochre Bio Announces Partnership with Boehringer Ingelheim to Develop Novel Regenerative Treatments for Patients with Advanced Liver Disease
2024-04-22
Earth Day Awareness: Hospitals Embrace Sustainability Efforts
2024-04-22
WHO Raises Alarm: Bird Flu Threat to Humans an ‘Enormous Concern’
2024-04-19
The Legal Battlefield of Weight-Loss Drugs: Eli Lilly and Novo Nordisk on the Defensive
2024-04-18
Pharmacogenomics in Asia-Pacific: Nalagenetics CEO Levana Sani Offers Insights and Strategies
2024-04-17
READ MORE
EVENT
2024-04-27
2024 Biomedical Final Pitch Competition
Room DA1620, Dana Building, Dana-Farber Cancer Institute, 99 Jimmy Fund Way, Boston, MA 02115
SEE MORE
Newsletter

Subscribe to receive updates.

SIGN UP
Facebook
Youtube
Twitter
Linkedin
About
Explore
More
© 2024 GeneOnline
Privacy Policy | Terms of Service
Privacy Policy | Terms of Service
  • Subscribe to our newsletter and dive into the world of biopharma with us.
SIGN UP
x
Scroll to Top